Interestingly, EGFR mutation was reported to induce NEK2 expression via the ERK signaling pathway, promoting in vitro NSCLC cell proliferation, and this NEK2 upregulation was found to impair the sensitivity of EGFR-targeting drugs [76]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.